A detailed history of Royal Bank Of Canada transactions in Selecta Biosciences Inc stock. As of the latest transaction made, Royal Bank Of Canada holds 66,554 shares of SELB stock, worth $55,905. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,554
Previous 115,206 42.23%
Holding current value
$55,905
Previous $79,000 30.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$0.62 - $0.85 $30,164 - $41,354
-48,652 Reduced 42.23%
66,554 $55,000
Q4 2023

Feb 14, 2024

SELL
$0.67 - $1.35 $8,716 - $17,563
-13,010 Reduced 10.15%
115,206 $79,000
Q3 2023

Nov 14, 2023

BUY
$1.02 - $1.23 $42,551 - $51,311
41,717 Added 48.23%
128,216 $135,000
Q2 2023

Aug 14, 2023

BUY
$1.04 - $1.4 $11,077 - $14,911
10,651 Added 14.04%
86,499 $96,000
Q1 2023

May 15, 2023

BUY
$1.15 - $1.89 $464 - $763
404 Added 0.54%
75,848 $105,000
Q4 2022

Feb 14, 2023

SELL
$0.96 - $1.6 $307 - $512
-320 Reduced 0.42%
75,444 $85,000
Q3 2022

Nov 14, 2022

BUY
$1.33 - $2.6 $1,016 - $1,986
764 Added 1.02%
75,764 $124,000
Q2 2022

Aug 15, 2022

SELL
$0.67 - $1.4 $4,124 - $8,618
-6,156 Reduced 7.59%
75,000 $98,000
Q1 2022

May 16, 2022

SELL
$1.23 - $3.31 $14,173 - $38,141
-11,523 Reduced 12.43%
81,156 $100,000
Q4 2021

Feb 14, 2022

BUY
$2.89 - $4.43 $25,619 - $39,271
8,865 Added 10.58%
92,679 $303,000
Q3 2021

Nov 15, 2021

BUY
$3.36 - $4.62 $6,286 - $8,644
1,871 Added 2.28%
83,814 $349,000
Q2 2021

Aug 16, 2021

BUY
$2.82 - $5.01 $231,079 - $410,534
81,943 New
81,943 $343,000

Others Institutions Holding SELB

About SELECTA BIOSCIENCES INC


  • Ticker SELB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 152,712,992
  • Market Cap $128M
  • Description
  • Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...
More about SELB
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.